This study is for people with a type of cancer called GEP-NETs (gastroenteropancreatic neuroendocrine tumors), which have grown even after specific treatments. These tumors have special features called SSTR+ (somatostatin receptor expressing), making them hard to operate on. The study will test a new drug, RYZ101, to see if it's safe and works well compared to usual treatments. In the first part of the study, researchers will find the best dose of RYZ101. In the second part, they'll compare its effects with the standard care treatments.
- Participation includes treatment with either RYZ101 or standard care.
- The study requires meeting specific health criteria and having certain test results.
- Participants cannot have certain conditions like heart problems or uncontrolled diabetes.
If you have questions or want more information, talk with your doctor to see if this study might be right for you.